This low FSP1 expression results from DNA hypermethylation, which can be reversed by decitabine (DEC), a DNA methyltransferase inhibitor, and tert‐butylhydroquinone (tBHQ), enhancing Nrf2‐FSP1 interaction and reducing leukaemia cell susceptibility to RSL3 [103]. Here, AIFM2 is linked to leukemia.